Summary
Bristol-Myers Squibb's (BMY) 2020 10-K filing reveals a year marked by significant integration following the Celgene acquisition, which impacted revenue streams and operational focus. The company is navigating the post-acquisition landscape, emphasizing growth from key in-line products and its pipeline, while also addressing the ongoing pressures of competition and evolving regulatory environments in the pharmaceutical industry. Investors should note the strategic importance of the Celgene integration, which is expected to drive long-term value through enhanced product portfolios in areas like oncology and immunology. The company's performance is closely tied to the success of its major therapeutic areas and its ability to innovate and bring new treatments to market amidst patent expirations and the rise of biosimilars. Diligence in monitoring R&D progress, commercial execution, and capital allocation strategies will be crucial for understanding BMY's future trajectory.
Financial Highlights
57 data points| Revenue | $42.52B |
| Cost of Revenue | $11.77B |
| Gross Profit | $30.75B |
| R&D Expenses | $10.05B |
| SG&A Expenses | $7.66B |
| Operating Expenses | $49.39B |
| Interest Expense | $1.42B |
| Net Income | -$9.02B |
| EPS (Basic) | $-3.99 |
| EPS (Diluted) | $-3.99 |
| Shares Outstanding (Basic) | 2.26B |
| Shares Outstanding (Diluted) | 2.26B |
Key Highlights
- 1The 2020 fiscal year was heavily influenced by the integration of the Celgene acquisition, impacting revenue and operational focus.
- 2Key growth drivers include established products within BMY's portfolio, particularly in oncology and immunology.
- 3Significant investment in Research and Development (R&D) continues, with a focus on advancing a robust pipeline of innovative therapies.
- 4The company is actively managing its product portfolio, balancing the lifecycle of existing drugs with the introduction of new treatments.
- 5BMY faces ongoing competition from other pharmaceutical companies and the increasing prevalence of generic and biosimilar drugs.
- 6The financial statements detail substantial assets and liabilities, reflecting the scale of operations and the impact of recent M&A activity.